Urticaria Chronic
Conditions
Brief summary
This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).
Interventions
DRUGPlacebo
Placebo solution nasal spray containing no active drug
DRUG0.5 mg epinephrine
0.5 mg epinephrine per spray
DRUG1 mg epinephrine
1 mg epinephrine per spray
Sponsors
ARS Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Is a male or female between the ages of 18 and 65 years, inclusive. * Has been clinically diagnosed with CSU and experiences an acute flare of moderate to severe urticaria symptoms (itch and hive severity UAS score ≥ 2) approximately 1-2 times a month or every other month consistently during the past year while on a chronic treatment. * Has been on a daily chronic treatment for ≥ 6 weeks. * Is willing to use a smartphone study application to record study assessments and AEs. * Has body weight more than 15 kilogram (kg). * Has no medical history of clinically significant hypertension and cardiovascular disease in the last 10 years * If female, is not pregnant or breastfeeding based on a negative urine pregnancy test at baseline. * Is able to communicate clearly with the Investigator and staff; able to read, complete questionnaires, and perform study procedures on the smartphone study application. * Is willing and able to provide written informed consent prior to participating in the study. * Controlled hypertension without beta blocker confirmed by the Investigator is acceptable. * At screening, has stable vital signs in the following ranges (after 5 minutes of rest): * Systolic blood pressure (SBP) ≥90 and ≤140 milliliters of mercury (mmHg) * Diastolic blood pressure (DBP) ≥50 and ≤90 mmHg * Heart rate (HR) ≥45 and ≤100 beats per minute (bpm)
Exclusion criteria
* Has a history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results. * Has any clinically significant medical condition or PE finding as deemed inappropriate by the Investigator. * Has abnormal cardiovascular exam at screening including any prior history of myocardial infarction or clinically significant abnormal electrocardiogram (ECG) * Has had significant traumatic injury or major surgery within 30 days prior to study screening. * Known hypersensitivity to any compound in the test product, or any other closely related compound (e.g., dihydropyridine-derived molecules). * Has participated in a clinical trial within 30 days prior to the first dose of study drug. * Has an immediate family member of the Investigator, or an employee of the study center, with direct involvement in the proposed study, or other studies under the direction of the Investigator or study center or is in a dependent relationship with a study center employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling), or may consent under duress.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch | 12 months | Change in itch scores (Uniform Assessment System) - Range is a scale of 0-3. Zero is none and 3 is severe. \[UAS\] as compared to placebo at each timepoint on exacerbation days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on hive | 12 months | Change in hive scores (Uniform Assessment System) - Range is a scale of 0-3. Zero is none and 3 is severe. \[UAS\] as compared to placebo at each timepoint on exacerbation days |
Countries
Germany, United States
Contacts
CONTACTOsnat Ehrman, MSc
Outcome results
None listed